TABLE 2

Selected NRF2 inducers acting as electrophilic modifiers of KEAP1

The reference corresponds to the code in ClinicalTrials.gov.

CompoundDiseaseClinical TrialReference
GraphicMultiple sclerosisApproved
PsoriasisApproved
Rheumatoid arthritisPhase IINCT00810836
Adult brain glioblastomaPhase INCT02337426
Cutaneous T cell lymphomaPhase IINCT02546440
Obstructive sleep apneaPhase IINCT02438137
Chronic lymphocytic leukemia small lymphocytic lymphomaPhase INCT02784834
GraphicMultiple sclerosisPhase IIINCT02634307
GraphicDiabetic nephropathyPhase IINCT00811889
Chronic kidney disease, T2DM, diabetic nephropathyPhase IIINCT01351675
Liver diseasePhase I/IINCT00550849
Hepatic impairmentPhase INCT01563562
Advanced solid tumors 
Lymphoid malignanciesPhase INCT00529438
NCT00508807
Alport syndromePhaseII/IIINCT03019185
Pulmonary hypertensionPhase IIINCT03068130
Pulmonary arterial hypertensionPhase IIINCT02657356
Renal insufficiency, T2DMPhase IINCT01053936
GraphicMitochondrial myopathyPhase IINCT02255422
Friedreich’s ataxiaPhase IINCT02255435
Inflammation and pain following ocular surgeryPhase IINCT02065375
Corneal endothelial cell loss, ocular pain and inflammation, cataract surgeryPhase IINCT02128113
MelanomaPhase I/IINCT02259231
Breast cancerPhase IINCT02142959
Non-small cell lung cancer, melanomaPhase INCT02029729
GraphicAcute kidney injuryPhase INCT02248051
GraphicHDPhase II/IIINCT00277355
Intracerebral hemorrhagePhase I/IINCT01805895
Retinitis pigmentosaPhase I/IINCT02140164
Intracerebral hemorrhagePhase I/IINCT03040128
GraphicNASHPhase IIINCT02068339
SchistosomiasisApproved
Lung cancerPhase INCT00006457
GraphicUlcerative colitisPreclinical PK——
GraphicCystic fibrosisPhase IINCT01315665
SchizophreniaPhase II/IIINCT02880462
Phase IINCT02810964
Phase IINCT01716858
COPDPhase IINCT01335971
Atopic asthmaticsPhase INCT01845493
AutismPhase IINCT01474993
Phase IINCT02909959
Phase IINCT02677051
Phase IINCT02654743
Phase I/IINCT02561481
HealthyPhase INCT01008826
Phase INCT02023931
MelanomaPhase INCT01568996
AsthmaPhase INCT01845493
Phase I/IINCT01183923
Prostate cancerPhase IINCT01228084
Breast cancerPhase IINCT00843167
Lung cancerPhase IINCT03232138
Environmental carcinogenesisPhase IINCT01437501
Alcohol sensitivityPhase IINCT01845220
AgingPhase IINCT03126539
Allergic rhinitisPhase IINCT02885025
Helicobacter pylori infectionPhase IVNCT03220542
T2DMPhase IINCT02801448
Head and neck squamous cell carcinoma, head and neck cancer, tobacco-related carcinomaPhase INCT03182959
GraphicSubarachnoid hemorrhagePhase IINCT02614742
Breast neoplasmPhase I/IINCT02970682
Prostate cancerPhase INCT02055716
NCT01948362
GraphicBrain ischemiaPreclinical PK
GraphicAlzheimer diseasePhase IINCT02711683
Acute ischemic strokePhase I/IINCT02149875
Vascular cognitive impairmentPhase II/IIINCT02993367
Cerebrovascular occlusion, collateral blood circulation, anterior cerebral circulation infarctionPhase IVNCT02594995
GraphicCholestasisPhase II/IIINCT00846963
HDPhase INCT00514774
Barrett esophagus, low-grade dysplasiaPhase IINCT01097304
Chronic hepatitis CPhase IIINCT00200343
T2DMPhase IINCT02033876
GraphicT2DMPhase INCT01677611
Colon cancerPhase INCT00256334
COPDPhase IIINCT02245932
Friedreich ataxiaPhase I/IINCT01339884
NASHPhase II/IIINCT02030977
Non-ischemic cardiomyopathyPhase IIINCT01914081
EndometriosisPhase IVNCT02475564
Chronic renal insufficiencyPhase IIINCT02433925
Metabolic syndrome XPhase IINCT02114892
Chronic subclinic inflammationPhase IIINCT01492114
ADPhase IINCT01504854
Phase IIINCT00743743
Colorectal cancerPhase INCT00433576
HDPhase IIINCT02336633
GraphicT2DM, cardiovascular riskPhase IVNCT01052025
Schizophrenia, cognition, psychosisPhase I/IINCT02104752
Acute kidney injury, abdominal aortic aneurysmPhase II/IIINCT01225094
Chronic kidney diseases, T2DMPhase II/IIINCT03262363
ADPhase I/IINCT00164749
NeoplasmsPhase IINCT02944578
Crohn's diseasePhase IIINCT02255370
Chronic schizophreniaPhase IVNCT02298985
Mild cognitive impairmentPhase IINCT01811381
Prostate cancerPhase IIINCT02064673
Major depressionPhase IVNCT01750359